Linked Life Data

21091806

Source:http://linkedlifedata.com/resource/pubmed/id/21091806

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-11-24
pubmed:abstractText
Drug-drug interactions can lead to reduced efficacy of medical treatment. Therapeutic failure may for instance result from combined treatment with an inhibitor of the specific pathway that is responsible for the generation of pharmacologically active drug metabolites. This problem may be overlooked in clinical practice. Several examples of drugs will be discussed -clopidogrel, losartan, tamoxifen and codeine - to illustrate differences in the potential impact on drug treatment in clinical practice. We conclude that the combined use of cytochrome P450-blocking serotonin reuptake inhibitors and tamoxifen or codeine should be avoided, whereas the situation is much more complex regarding the use of proton pump inhibitors together with clopidogrel, and the evidence regarding cytochrome P450 inhibitor-dependent activation of losartan is inconclusive.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1365-2796
pubmed:author
pubmed:copyrightInfo
© 2010 The Association for the Publication of the Journal of Internal Medicine.
pubmed:issnType
Electronic
pubmed:volume
268
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
540-8
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice.
pubmed:affiliation
Karolinska Institutet, Department of Clinical Science and Education at Södersjukhuset, Division of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't